Migraine Market to Progress at a CAGR of 10.96% by 2032 | DelveInsight

15 Jun 2022
www.prnewswire.com
Generic DrugImmunotherapy
The migraine market is expected to surge due to the increasing prevalence of the disease along with increasing awareness during the forecast period. Furthermore, the launch of various multiple-stage pipeline products will significantly revolutionize the migraine market dynamics.
LAS VEGAS, June 15, 2022 /PRNewswire/ -- DelveInsight's
MigraineMigraine Market Insights report includes a comprehensive understanding of current treatment practices, Migraine emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into 7MM (the United States, the EU5 (the United Kingdom, Italy, Spain, France, and Germany), and Japan.
Key Takeaways from the Migraine Market Report
As per DelveInsight analysis, the migraine market size in the 7MM was approximately
USD 6.9 billion in 2021.
As per the estimates, the total Migraine prevalent cases in the 7MM was approximately
118 million in 2021.
Leading Migraine companies such as
, and others are developing novel migraine drugs which can be available in the migraine market in the upcoming years.
The migraine therapies in the pipeline include
BHV-3500 (Zavegepant), Atogepant, INP104, Zolmitriptan transdermal, AXS-07, Lu AG09222, ABP-450, IONIS-PKKRx, Oral CL- H1T, LY-3451838, and others.
The increased number of migraine cases and the emerging treatment are likely to contribute directly to the migraine market growth during the forecast period.
Discover more about therapies set to grab major migraine market share @
Migraine Market Landscape
Migraine is the seventh most debilitating disease in the world (responsible for 2.9% of all years of life lost to disability/YLDs) and the leading cause of impairment among all neurological disorders. Migraine is classed as chronic or episodic based on the type of the attack and its frequency. Episodic migraine is defined as having 0–14 headache days per month, and chronic migraine is defined as having 15 or more headache days per month.
Although migraine symptoms usually include severe throbbing recurring pain on one side of the head, one-third of migraine attacks are found to be affected on both sides. Among the most common migraine causes include stress, physical factors, food additives, and others. MRI and CT scans are mainly used for migraine diagnosis.
Migraine Epidemiology Segmentation
As per DelveInsight, there were approx
118 million Migraine prevalent cases in the 7MM in 2021.
Among the EU5 countries, Germany had the highest migraine prevalence in 2021.
The
Migraine market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:
Total Prevalence of Migraine
Prevalent Cases of Migraine by severity
Gender-specific Prevalence of Migraine
Diagnosed Cases of Episodic and Chronic Migraine
Download the report to understand which factors are driving migraine epidemiology trends @
Migraine Epidemiological Insights
The key revenue-generating components of the acute migraine treatment market can be roughly characterized as triptans, NSAIDs, analgesics/opioids, and DHE (dihydroergotamine) or ergot alkaloids. Triptans continue to dominate the entire acute therapy landscape in terms of revenue generation. Some of the major migraine drugs (generics/branded) belonging to this class are
Moreover, preventive/prophylactic treatment is used to minimize the frequency, intensity, and duration of migraine attacks. Preventive migraine medicines approved by the FDA include
propranolol, timolol, divalproex sodium, OnabotulinumtoxinA (botox), and topiramate; other drugs have demonstrated effectiveness but need FDA clearance.
Apart from these, the other FDA approved drugs used for migraine treatment are
Vyepti (Eptinezumab) (Lundbeck Seattle BioPharmaceutical), Emgality (Galcanezumab-gnlm) (Eli Lilly and Company), Aimovig (Amgen/Novartis), Ajovy (Teva Pharmaceuticals), Ubrelvy (Allergan), Rimegepant (Nurtec ODT) (Biohaven Pharmaceuticals), and others.
To know more about migraine treatment, visit @
Migraine Pipeline Therapies and Key Companies
Atogepant: AbbVie
Lu AG09222: Lundbeck
Oral CL- H1T: Charleston Laboratories
Learn more about the migraine medicine in clinical trials @
The migraine treatment market looks promising as the market is emerging with
newer treatments that have recently been approved by the FDA and are anticipated for approval in the coming years. A large
number of clinical phase trials are being done to examine and evaluate promising investigational therapies and their much-awaited launch owing to a robust therapeutic treatment market and bolstering the treatment response as a whole. Moreover, the
increasing disease prevalence and awareness will fuel the migraine market during the forecast period.
However, some factors are hindering the growth of the migraine market. Despite the availability of standard treatment guidelines across regions and the well-entrenched presence of an array of available,
mostly inexpensive options,
current abortive and prophylactics,
lack of biomarkers, and
lack of therapies for pediatric patients exist as a high unmet need which is contrary to the popular perception. The therapies addressed in recent are not effective in all patients, have contraindications related to cardiovascular conditions in some patients, and are nonspecific or
poorly tolerated in others. In addition, the
undiagnosed, unreported cases and the unawareness about the disease remain the primary aspects that strive for the migraine market growth.
Scope of the
Market Report
Study Period: 2019–2032
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
Key
Key
Therapies: BHV-3500 (Zavegepant), Atogepant, INP104, Zolmitriptan transdermal, AXS-07, Lu AG09222, ABP-450, IONIS-PKKRx, Oral CL- H1T, LY-3451838, and others
Therapeutic Assessment: Migraine current marketed and emerging therapies
Market Dynamics:  Migraine market drivers and barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
Unmet Needs, KOL's views, Analyst's views,
Discover more about migraine drugs in development @
Migraine Clinical Trials
Table of Contents
Get in touch with our Business executive  @
Healthcare Due Diligence Services
Related Reports
Migraine Epidemiology
Migraine Epidemiology Forecast to 2032 report delivers an in-depth understanding of the disease, historical, and forecasted Migraine epidemiology in the 7MM.
Migraine Pipeline Insight, 2022 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key Migraine companies including
Allergan, Biohaven Pharmaceuticals, Dr. Reddy's Labs, AbbVie, among others.
Cluster Headache Market
Cluster Headache Market Insights, Epidemiology, and Market Forecast-2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key Cluster Headache companies including
Cluster Headache Epidemiology
Cluster Headache Epidemiology Forecast to 2032 report delivers an in-depth understanding of the disease, historical, and forecasted Cluster Headache epidemiology in the 7MM.
Cluster Headache Pipeline
Cluster Headache Pipeline Insight, 2022 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key Cluster Headache companies including
Other Trending Reports
Glomerulonephritis Market
|
Lymphedema Market
|
Audiology Devices Market
|
|
Varicose Veins Market
|
Nasolabial Fold Market
|
|
Scleritis Market
|
Contrast-Induced Nephropathy Market | Mucinous cystic neoplasms Market | Metastatic Uveal Melanoma Market | ICOS-Next Generation Immunotherapy Market | Herpes Simplex Market | Hepatitis C Market | Guillain-Barre Syndrome Market | Graft Versus Host Disease Market | Goitre Market
Related Healthcare Blogs
Neuromodulation Devices in Migraine
Migraine Market Outlook
About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.  Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve
.
Connect with us on LinkedIn
|Facebook|Twitter
Contact Us
[email protected]
+1(919)321-6187
www.delveinsight.com
Logo: https://mma.prnewswire.com/media/1082265/DelveInsight_Logo.jpg
SOURCE DelveInsight Business Research, LLP
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
Drugs
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.